{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027346","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.157684+00:00","generated_at":"2026-06-11T22:55:19.279024+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent","bullets":["Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.","Net loss $4.7M ($0.44/shr) vs $4.5M ($0.41/shr) in Q2 2022; R&D expenses up to $3.6M from $3.0M.","FDA cleared IND for LP-184; Phase 1 basket trial activated for solid tumors and brain cancers.","LP-284 IND submission expected August 2023; Phase 1 trial targeted for Q4 in non-Hodgkin's lymphomas.","Dosed first patients in Phase 2 Harmonic trial for never-smoker NSCLC; RADR collaboration with Bielefeld University for ADCs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027346","json":"https://secwatch.observer/filing/0001493152-23-027346.json","markdown":"https://secwatch.observer/filing/0001493152-23-027346.md","text":"https://secwatch.observer/filing/0001493152-23-027346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/0001493152-23-027346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:55:19.279024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0c91b47b545c006946c0a4b3990299904844719","claim":"Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/0001493152-23-027346-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}